Condition: Advanced (Unresectable or Metastatic) Melanoma · Sponsor: mAbxience Research S.L.
This is a randomised, multicentre, multinational, double-blind, integrated study to sompare the pharmacokinetics, efficacy, safety, and immunogenicity of MB11 versus Opdivo® in subjects with previously untreated advanced (unresectable or Metastatic) Melanoma
This description comes directly from the study's public registry record.
Susana Millán, PhD · +34917711500 · Susana.Millan@mabxience.com
Camino Huerga · +34917711500 · Camino.Huerga@mabxience.com
Always discuss trial participation with your own doctor first.
| Site 111003 | Funchal, Portugal | Recruiting |
| Site 117015 | Chernivtsi, Ukraine | Recruiting |
| Site 117005 | Ivano-Frankivsk, Ukraine | Recruiting |
| Site 117002 | Kyiv, Ukraine | Recruiting |
| Site 117006 | Kyiv, Ukraine | Recruiting |
| Site 117007 | Kyiv, Ukraine | Recruiting |
| Site 117012 | Kyiv, Ukraine | Recruiting |
| Site 117013 | Kyiv, Ukraine | Recruiting |
| Site 117014 | Kyiv, Ukraine | Recruiting |
| Site 117016 | Kyiv, Ukraine | Recruiting |
| Site 117017 | Kyiv, Ukraine | Recruiting |
| Site 117018 | Kyiv, Ukraine | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07221734